Germany's Draegerwerk Q1 net sales rise 6.9%, EBIT improves

Draegerwerk AG & Co KGaA

30/04/2026 06:45

Overview

Germany medical and safety tech firm's Q1 net sales rose yr/yr

Q1 EBIT improved significantly, supported by higher sales, margin gains, and lower costs

Order intake exceeded prior-year level, driven by growth in Germany and medical division

Outlook

Draegerwerk expects 2026 net sales to rise 1.0% to 5.0%

Company sees 2026 EBIT margin between 5.0% and 7.5%

Company says strong order intake and operational momentum support full-year outlook

Result Drivers

GERMANY DEMAND - Co said order intake growth was mainly due to significant demand increase in Germany

MEDICAL DIVISION GROWTH - Medical division order intake and sales rose, with nearly all product areas and services contributing

COST DECLINE - Lower functional expenses, partly due to prior-year one-off payments, supported earnings improvement

Company press release: ID:nEQNwPXWa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
EUR 755.90 mln
EUR 761 mln (2 Analysts)
Q1 Orders
EUR 864.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Draegerwerk AG & Co KGaA is €94.00, about 35.8% above its April 29 closing price of €69.20

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)